PFE - Pfizer Inc.

NYSE - NYSE Delayed price. Currency in USD
37.33
-0.03 (-0.08%)
At close: 4:04PM EDT

37.14 -0.19 (-0.51%)
After hours: 5:52PM EDT

Stock chart is not supported by your current browser
Previous close37.36
Open37.20
Bid0.00 x 0
Ask0.00 x 0
Day's range37.12 - 37.33
52-week range32.32 - 39.43
Volume14,793,271
Avg. volume20,500,350
Market cap218.364B
Beta0.92
PE ratio (TTM)10.37
EPS (TTM)3.60
Earnings date31 Jul 2018
Forward dividend & yield1.36 (3.66%)
Ex-dividend date2018-08-02
1y target est39.80
Trade prices are not sourced from all markets
  • Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board
    Yahoo Finance Video2 days ago

    Business + Coffee: Novartis delays price hikes, US govt pays Trump golf course, Papa John fights board

    Wednesday, July 18: Novartis says it will follow Pfizer in delaying planned price hikes after pressure from Trump; US government paid $77,000 to President Donald Trump’s Turnberry golf resort in Scotland before he stayed there; Papa John Schnatter says he regrets resigning as chairman of Papa John’s and is fighting back against the board. Yahoo Finance’s Dan Roberts serves up the news of the day -- on his birthday!

  • Johnson & Johnson’s Revenues Came in ahead of Estimates in Q2
    Market Realist4 hours ago

    Johnson & Johnson’s Revenues Came in ahead of Estimates in Q2

    Johnson & Johnson (JNJ) announced its Q2 2018 earnings results on July 17. JNJ stock rose ~3.5% on the day and ended at a closing price of $129.12. On July 16, the stock closed at $124.69.

  • Barrons.com7 hours ago

    [$$] Big Bet on Pfizer for a Market-Beating Investment Firm

    Returns for the firm’s largest fund, Jensen Quality Growth (JENSX), continue to top the S&P 500, including over the past 10 years through June 30. Other large second-quarter moves include taking large cuts to positions in Nike (NKE) and Mastercard (MA), and trimming back in Coca-Cola (KO) and Microsoft (MSFT). Jensen hasn’t yet responded to a request for comment.

  • Roche Takes Drug-Price Posturing to New Heights
    Bloomberg8 hours ago

    Roche Takes Drug-Price Posturing to New Heights

    Pfizer Inc. started things off earlier this month by agreeing to roll back mid-year price hikes and delay them — for a few months. Similar efforts announced this week by Novartis AG and Merck & Co. arguably won’t be any more consequential. In a statement Friday, the Swiss pharmaceutical giant said it told the Health and Human Services Department on July 11 that it wouldn’t enact any more price hikes in 2018.

  • Analysts’ Estimates and Recommendations for Allergan on July 19
    Market Realist10 hours ago

    Analysts’ Estimates and Recommendations for Allergan on July 19

    Allergan’s stock price has fallen nearly 28.4% over the last 12 months, but it’s risen ~7.5% year-to-date in 2018. Analysts’ estimates show that the stock has the potential to return ~17.7% over the next 12 months.

  • Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy
    Zacks11 hours ago

    Merck to Cut Price of Few Drugs Amid Drug Pricing Controversy

    Merck (MRK) announces a 60% cut in U.S. list prices for its hepatitis C drug, Zepatier. It will also lower the list price of some other drugs by 10%.

  • 3 Stocks That Could Be Added to the Dow Next
    Motley Fool12 hours ago

    3 Stocks That Could Be Added to the Dow Next

    There have been over 50 component changes to the Dow's since 1896, and these three stocks could be the next to join the prestigious index.

  • Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals
    Zacks12 hours ago

    Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

    J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

  • How Celgene’s Abraxane and Otezla Are Positioned ahead of Q2 2018
    Market Realistyesterday

    How Celgene’s Abraxane and Otezla Are Positioned ahead of Q2 2018

    Celgene’s (CELG) Abraxane reported revenue of $262 million in the first quarter, reflecting an ~11.0% YoY (year-over-year) rise. Abraxane’s sales grew 12.0% in the US market to reach $159.0 million. In the international market, its sales grew 9.6% to reach $103 million. Otezla and other drugs’ revenue trends

  • Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study
    Zacksyesterday

    Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

    Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

  • Better Buy: Novavax, Inc. vs. Pfizer
    Motley Fool2 days ago

    Better Buy: Novavax, Inc. vs. Pfizer

    Novavax and Pfizer have been chronic underachievers, but their stocks may soon perk up. Here's a look at which stock is the better buy right now.

  • Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.
    Bloomberg3 days ago

    Novartis Joins Pfizer in Holding Line on Drug Prices in U.S.

    Swiss drugmaker Novartis AG is holding the line on U.S. prices this year as an attack from President Donald Trump led rival Pfizer Inc. to delay planned increases for some medicines. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday.

  • Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year
    Bloomberg3 days ago

    Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year

    Swiss drugmaker Novartis AG is holding the line on prices in the U.S. this year, following a move by rival Pfizer Inc. to delay planned increases for some medicines after President Donald Trump launched an attack on the U.S. pharma giant. Novartis has voluntarily pulled back on increasing prices in the U.S., Chief Executive Officer Vas Narasimhan said on a call Wednesday with journalists. Pfizer last week agreed to defer planned price increases for certain drugs a day after Trump targeted Pfizer over reported plans to implement a series of price increases, criticizing the move on Twitter and briefly rattling its shares.

  • Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
    Zacks3 days ago

    Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III

    Pfizer (PFE) initiates phase III program on a gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B.

  • Pfizer's Reorganizing Again. Is Its Stock a Buy Now?
    Motley Fool4 days ago

    Pfizer's Reorganizing Again. Is Its Stock a Buy Now?

    The drugmaker's second reorganization in four years signals where the company is headed. But it doesn't solve its most serious problem.

  • Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
    Zacks5 days ago

    Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population

    FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.

  • With General Electric Gone, Which Dow Component Will Be Kicked Out Next?
    Motley Fool5 days ago

    With General Electric Gone, Which Dow Component Will Be Kicked Out Next?

    Three Dow stocks could be on the hot seat, but one looks like a sure shot to be shown the door next year.

  • Novartis Looks to Exit Antibacterial, Antiviral Program
    Zacks7 days ago

    Novartis Looks to Exit Antibacterial, Antiviral Program

    Per media sources, Novartis is looking to exit its antibacterial and antiviral research program, and cut its headcount.

  • Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
    Zacks8 days ago

    Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit

    Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.

  • Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize
    Zacks8 days ago

    Dow 30 Stock Roundup: Boeing Q2 Commercial Deliveries Up Y/Y, Pfizer to Reorganize

    The index enjoyed a strong week of gains, boosted by expectations of a strong second quarter earnings season.

  • Financial Times8 days ago

    [$$] Pfizer boss humbled after ‘man to man’ talk with Donald Trump

    When Ian Read decided to hoist the price of 100 products earlier this month, the Pfizer chief executive was unprepared for the fallout. Shortly after, he received a telephone call from Alex Azar, the health secretary, who warned him the President was not bluffing. “Alex conveyed that Mr Trump was very angry with Pfizer,” said one person briefed on the call.

  • Pfizer (PFE) to Reorganize Business Into Three New Units
    Zacks8 days ago

    Pfizer (PFE) to Reorganize Business Into Three New Units

    Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.

  • Is Pfizer (PFE) Outperforming Other Medical Stocks This Year?
    Zacks8 days ago

    Is Pfizer (PFE) Outperforming Other Medical Stocks This Year?

    Is (PFE) Outperforming Other Medical Stocks This Year?

  • 3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018
    Zacks8 days ago

    3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018

    Gene therapy continues to be in focus with the recent spate of deals and acquisitions. We highlight three stocks, which have promising candidates in their pipeline.

  • Financial Times9 days ago

    [$$] The drug pricing playbook: how pharma companies keep costs high

    Less than 48 hours after Donald Trump took to Twitter to say the company “should be ashamed” of raising prices on 100 products, the drugmaker demurred and said it would defer the increases. also followed a series of thinly veiled warnings from Alex Azar, the health secretary, who said its decision to raise prices this month would “be remembered for creating a tipping point in US drug pricing policy”. The company said it would defer the increases until the end of the year or until Mr Trump implements his “blueprint to strengthen the healthcare system” — a complex string of measures announced in May, aimed at lowering drug prices.